WallStSmart
TEVA

Teva Pharma Industries Ltd ADR

NYSE: TEVA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$35.38
+11.89% today

Updated 2026-04-29

Market cap
$41.20B
P/E ratio
26.40
P/S ratio
2.39x
EPS (TTM)
$1.34
Dividend yield
—
52W range
$15 – $37
Volume
6.7M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Teva Pharma Industries Ltd ADR (TEVA) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$35.38
Consensus
$37,380.00
+105552.91%
2030 Target
$216.58
+512.15%
DCF
$63.58
+46.04% MoS
8 analysts:
4 Buy1 Hold0 Sell

Management guidance

Teva management targets biosimilars business growth of $400 million by 2027, representing a strategic pivot from generics to higher-margin innovative products. CEO Richard Francis emphasized 'Pivot to Growth' strategy with FDA approvals for PONLIMSI (Prolia biosimilar) and acceptance of Xolair biosimilar application. No specific total company revenue targets were disclosed in recent guidance.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$357.95
$20.9B Rev × 20x P/S
Base case (2030)
$216.58
$20.9B Rev × 12x P/S
Bear case (2030)
$144.38
$20.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$15.8B$16.5B$17.3B$17.1B$17.9B$18.6B$19.7B$20.9B
Revenue growth—4.4%4.3%-0.9%4.4%4.4%5.5%6.1%
EPS$2.56$1.41$2.92$2.76$3.18$3.65$4.12$4.68
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$177.47$183.49$192.51$201.54$216.58

Catalysts & risks

Growth catalysts
+ PONLIMSI (denosumab biosimilar) FDA approval and market launch in 2026-2027
+ Xolair biosimilar FDA and EMA review completion (both applications accepted)
+ duvakitug Phase 2b data in ulcerative colitis/Crohn's disease with Sanofi partnership
+ $400M Blackstone strategic growth investment for pipeline advancement
+ TEV-325 (AI-designed biologic) entry into clinical trials in 2027
+ Generic drug market stabilization in 2026 after pricing pressure decline
Key risks
- Generics pricing pressure and 5-year revenue CAGR of only 0.7% reflects structural decline
- Geopolitical risk: March 2026 missile strike near Neot Hovav manufacturing facility in Israel
- Biosimilar adoption uncertainty and competition from established players (Amgen, Sandoz)
- High debt levels (Debt/Equity 2.17x) limit financial flexibility for R&D investment
- Delayed pipeline catalysts could push revenue inflection beyond 2027
- Patent cliffs on branded products offsetting biosimilar growth

Methodology

Teva Pharma Industries Ltd ADR's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 8 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.